These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 22466117)
1. Positivity for anti-RNP antibody is a risk factor for adverse effects caused by trimethoprim-sulfamethoxazole, a prophylactic agent for P. jiroveci pneumonia, in patients with connective tissue diseases. Maezawa R; Kurasawa K; Arai S; Okada H; Owada T; Fukuda T Mod Rheumatol; 2013 Jan; 23(1):62-70. PubMed ID: 22466117 [TBL] [Abstract][Full Text] [Related]
2. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Vananuvat P; Suwannalai P; Sungkanuparph S; Limsuwan T; Ngamjanyaporn P; Janwityanujit S Semin Arthritis Rheum; 2011 Dec; 41(3):497-502. PubMed ID: 21959291 [TBL] [Abstract][Full Text] [Related]
3. Adverse drug reactions to trimethoprim-sulfamethoxazole in systemic lupus erythematosus. Izuka S; Yamashita H; Takahashi Y; Kaneko H Lupus; 2021 Sep; 30(10):1679-1683. PubMed ID: 34304628 [TBL] [Abstract][Full Text] [Related]
4. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257 [TBL] [Abstract][Full Text] [Related]
5. A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases. Takenaka K; Komiya Y; Ota M; Yamazaki H; Nagasaka K Mod Rheumatol; 2013 Jul; 23(4):752-8. PubMed ID: 22907597 [TBL] [Abstract][Full Text] [Related]
6. Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole. Beumont MG; Graziani A; Ubel PA; MacGregor RR Am J Med; 1996 Jun; 100(6):611-6. PubMed ID: 8678080 [TBL] [Abstract][Full Text] [Related]
7. Comparison of trimethoprim-sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease. Kimura M; Tanaka S; Ishikawa A; Endo H; Hirohata S; Kondo H Rheumatol Int; 2008 May; 28(7):673-6. PubMed ID: 18080124 [TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophylaxis of Harada T; Kato R; Sueda Y; Funaki Y; Takata M; Okazaki R; Hasegawa Y; Yamasaki A Mod Rheumatol; 2021 May; 31(3):629-635. PubMed ID: 32820678 [TBL] [Abstract][Full Text] [Related]
9. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole. Fisher RG; Nageswaran S; Valentine ME; McKinney RE AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767 [TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids. Jinno S; Akashi K; Onishi A; Nose Y; Yamashita M; Saegusa J Rheumatol Int; 2022 Aug; 42(8):1403-1409. PubMed ID: 34263352 [TBL] [Abstract][Full Text] [Related]
11. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. Godeau B; Coutant-Perronne V; Le Thi Huong D; Guillevin L; Magadur G; De Bandt M; Dellion S; Rossert J; Rostoker G; Piette JC J Rheumatol; 1994 Feb; 21(2):246-51. PubMed ID: 8182632 [TBL] [Abstract][Full Text] [Related]
12. Inhaled pentamidine for Pneumocystis jiroveci prophylaxis in a heart transplant recipient with allergy for trimethoprim sulfamethoxazole. Altintas G; Diken AI; Diken OE; Hanedan O; Kucuker SA Exp Clin Transplant; 2011 Feb; 9(1):72-3. PubMed ID: 21605028 [TBL] [Abstract][Full Text] [Related]
17. [Clinical characteristics of Pneumocystis carinii pneumonia in children with systemic lupus erythematosus]. Tang XY; Li J; Dong F; Song HM Zhonghua Er Ke Za Zhi; 2013 Dec; 51(12):920-4. PubMed ID: 24495763 [TBL] [Abstract][Full Text] [Related]
18. Preventive effect of sulfamethoxasole-trimethoprim on Pneumocystis jiroveci pneumonia in patients with interstitial pneumonia. Enomoto T; Azuma A; Matsumoto A; Nei T; Fujita K; Hattori K; Saito Y; Abe S; Usuki J; Kudoh S Intern Med; 2008; 47(1):15-20. PubMed ID: 18175999 [TBL] [Abstract][Full Text] [Related]
19. A Four-Center Retrospective Study of the Efficacy and Toxicity of Low-Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Pneumonia in Patients without HIV Infection. Kosaka M; Ushiki A; Ikuyama Y; Hirai K; Matsuo A; Hachiya T; Hanaoka M Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893787 [TBL] [Abstract][Full Text] [Related]
20. Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial. Utsunomiya M; Dobashi H; Odani T; Saito K; Yokogawa N; Nagasaka K; Takenaka K; Soejima M; Sugihara T; Hagiyama H; Hirata S; Matsui K; Nonomura Y; Kondo M; Suzuki F; Tomita M; Kihara M; Yokoyama W; Hirano F; Yamazaki H; Sakai R; Nanki T; Koike R; Kohsaka H; Miyasaka N; Harigai M Arthritis Res Ther; 2017 Jan; 19(1):7. PubMed ID: 28100282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]